Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is Buntanetap, an orally administered drug that has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, and is also in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting against traumatic brain injury and stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio was incorporated in 2008 and is based in Berwyn, Pennsylvania.
| Symbol | ANVS |
|---|---|
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
| CEO | Maria L. Maccecchini |
| Employees | 8 |
| Headquarters | Malvern, PA, US |
| IPO | 2020-01-29 |
| Website | www.annovisbio.com |